Why Is Genius Sports Limited (GENI) Stock Down -11% Today?
Key Takeaways
- GENI shares tumbled approximately 11.14% in after-hours trading Wednesday, extending a sharp intraday sell-off from the prior close of $6.87 to a post-market level near $6.11.
- The primary catalyst was aggressive profit-taking after a blistering 35% rally that carried the stock from roughly $5.30 in late May to above $7.20 by mid-June.
- Lingering concerns over the company's Q1 2026 earnings miss and a series of analyst price-target cuts continued to weigh on sentiment.
- Positive fundamental developments — including an NCAA data partnership extension through 2032 and an expanded bet365 streaming deal — failed to offset the selling pressure.
- The stock is now testing a critical technical support zone between $6.00 and $6.30, with traders watching whether buyers will defend this level or a deeper correction toward the mid-$5 range will unfold.
- Broader market caution and elevated short interest of roughly 9.4% of the float added to the downward momentum.
What Drove the Sharp Sell-Off in GENI
GENI, the stock of Genius Sports Limited — a global sports data, technology, and media company that provides official data feeds, live streaming, and integrity services to leagues, sportsbooks, and broadcasters worldwide — suffered a steep decline in Wednesday's trading session. After closing the previous session at $6.87, the stock fell sharply during regular trading and continued to slide in after-hours action, reaching approximately $6.11, a drop of 11.14%. The sell-off was driven primarily by profit-taking following a powerful multi-week rally, compounded by residual unease over the company's path to sustained profitability and recent analyst estimate reductions.
Profit-Taking After a Powerful June Rally
The most immediate driver behind Wednesday's plunge was a classic profit-taking cycle. From late May through mid-June, GENI staged an eye-catching advance, surging approximately 35% from the $5.30 area to an intraday peak above $7.20 on June 11. That kind of rapid appreciation in a speculative, growth-oriented name frequently invites short-term traders and momentum players to lock in gains, and Wednesday's price action reflected exactly that dynamic. Intraday charts showed a steady fade from premarket highs near $7.00 down through the $6.50s and into the low $6.30s during the afternoon, with after-hours trading extending the decline further. The velocity of the reversal suggests that stop-loss triggers and algorithmic selling may have amplified the move once key intraday levels broke. I also checked this setup using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Overhang and Analyst Target Cuts
Beneath the technical profit-taking, fundamental concerns continued to cast a shadow. Genius Sports reported Q1 2026 results on May 7 that delivered a mixed picture: revenue of $187.95 million beat consensus estimates by nearly 10%, but earnings per share of -$0.21 missed the -$0.09 consensus by a wide margin. In the weeks following the report, several Wall Street firms lowered their price targets — Needham moved from $14 to $10, BTIG from $10 to $9, and Citigroup from $9 to $8 — while Stifel reiterated a Hold rating with a $5 target. Although the majority of analysts still rate the stock a Buy, the downward revisions reinforced a narrative that the company's path to consistent profitability remains uncertain, leaving the stock vulnerable to sharp pullbacks during risk-off episodes.
Technical Breakdown and Key Support Levels
Wednesday's sell-off carried significant technical implications. The stock sliced back below its 200-day moving average near $7.03 — a level it had briefly reclaimed during the rally — and is now testing a support band between $6.00 and $6.30, an area where buyers previously stepped in during early June. The 50-day moving average sits lower, near $5.09, providing a secondary floor if the current support zone fails. With a beta of approximately 1.90, GENI tends to amplify broader market moves, and any further deterioration in risk appetite could accelerate a test of lower levels. Elevated volume on the decline — well above the daily average — confirmed strong institutional and retail participation in the move.
Positive Catalysts Overwhelmed by Selling Pressure
Notably, Wednesday's rout occurred despite a stream of fundamentally positive announcements. On the very same day, Genius Sports and the NCAA announced a major extension of their data and technology partnership through 2032, securing exclusive rights to distribute official NCAA data to licensed sportsbooks and introducing a new Authorized Gaming Licensee program. Just days earlier, the company unveiled an expanded live streaming and data partnership with bet365, and on June 10 it announced a Liga MX and Polymarket sponsorship agreement with Genius Sports providing official data and integrity infrastructure. That such substantive commercial wins failed to cushion the stock underscores the degree to which short-term technical and sentiment factors dominated trading on Wednesday.
Market Context and Trading Activity
The sell-off in GENI was not occurring in isolation. Broader market sentiment has been cautious amid geopolitical uncertainties and mixed economic data, and small-cap growth names with negative earnings have been particularly susceptible to rotation out of risk assets. Peer sports data and betting-related stocks such as SRAD (Sportradar) also faced pressure during the session. Trading volume in GENI surged well above the 10-day average, indicating that the move was driven by conviction selling rather than a low-liquidity drift. Short interest remains elevated at roughly 9.4% of the float, and while the days-to-cover ratio of approximately 2.68 is manageable, the sizable short position likely contributed to the intensity of the downward move as momentum traders piled on.
Turning to AI Tools for Perspective on Volatility
In volatile market environments like the one affecting GENI today, I often turn to data-driven tools to help navigate rapid price swings. Tickeron's Trending AI Robots page features a curated selection of hundreds of AI-powered trading bots that cover thousands of tickers across multiple strategies and timeframes. Only the strongest-performing bots under current market conditions are showcased in this dynamically updated section, allowing users to observe which algorithms are successfully adapting to real-time volatility. Bots vary by strategy type, performance metrics, and traded symbols, offering a diverse view of automated approaches to stock selection and timing. Exploring the Trending AI Robots page has given me valuable perspective on how systematic strategies are interpreting the same market conditions that drove today's sharp move in GENI.
What Comes Next for GENI
The immediate focus for traders and investors centers on whether GENI can hold the $6.00 support level. A successful defense of this zone, particularly with a high-volume reversal candle, would suggest the pullback is a healthy consolidation within a broader recovery attempt. A decisive break below $6.00, however, would open the door to a retest of the mid-$5 range and potentially the 50-day moving average. Looking further ahead, the company's next earnings report is estimated for August 5, 2026, and the approaching FIFA World Cup and NFL season represent significant potential revenue catalysts given Genius Sports' deep official data partnerships with both ecosystems. The integration of the Legend acquisition and the ramp-up of the GeniusIQ AI platform will also be closely monitored for signs of accelerating growth. Risks include further analyst estimate revisions, potential equity dilution from acquisition-related share issuance, and any regulatory headwinds affecting the sports betting industry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Aroon Indicator for GENI shows an upward move is likely
GENI's Aroon Indicator triggered a bullish signal on August 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 181 similar instances where the Aroon Indicator showed a similar pattern. In of the 181 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where GENI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 20, 2026. You may want to consider a long position or call options on GENI as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GENI moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for GENI turned negative on August 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GENI broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GENI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.154) is normal, around the industry mean (5.870). P/E Ratio (0.000) is within average values for comparable stocks, (29.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (32.334). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (2.717) is also within normal values, averaging (57.320).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry InternetSoftwareServices
Advertisement